Although many cancers initially respond to cisplatin (CDDP)-based chemotherapy, resistance frequently develops. Insulin-like growth factor-binding protein-3 (IGFBP-3) silencing by promoter methylation is involved in the CDDP-acquired resistance process in non-small cell lung cancer (NSCLC) patients. Our purpose is to design a translational-based profile to predict resistance in NSCLC by studying the role of IGFBP-3 in the phosphatidyl inositol 3-kinase (PI3K) signaling pathway. We have first examined the relationship between IGFBP-3 expression regulated by promoter methylation and activation of the epidermal growth factor receptor (EGFR), insulin-like growth factor-I receptor (IGFIR) and PI3K/AKT pathways in 10 human cancer cell lines and 25 NSCLC patients with known IGFBP-3 methylation status and response to CDDP. Then, to provide a helpful tool that enables clinicians to identify patients with a potential response to CDDP, we have calculated the association between our diagnostic test and the true outcome of analyzed samples in terms of cisplatin IC 50 ; the inhibitory concentration that kills 50% of the cell population. Our results suggest that loss of IGFBP-3 expression by promoter methylation in tumor cells treated with CDDP may activate the PI3K/AKT pathway through the specific derepression of IGFIR signaling, inducing resistance to CDDP. This study also provides a predictive test for clinical practice with an accuracy and precision of 0.84 and 0.9, respectively, (P ¼ 0.0062). We present a biomarker test that could provide clinicians with a robust tool with which to decide on the use of CDDP, improving patient clinical outcomes.
INTRODUCTION
Advanced non-small cell lung cancer (NSCLC), accounts for one out of six cancer-related deaths worldwide, 1 mainly secondary to late diagnosis and intrinsic or acquired resistance to available therapies. Platinum-induced DNA hypermethylation may be one of the mechanisms involved in the development of resistant phenotypes by inactivating genes required for drug cytotoxicity. 2, 3 Unfortunately, in disseminated patients without epidermal growth factor receptor (EGFR) mutations or ALK-EML4 expression in their tumors, the standard treatment is based on platinum doublets but clinical probability to achieve an objective response or increased survival after a cisplatin (CDDP)-based therapy for metastatic disease is o40%. 4 Insulin-like growth factor-binding protein-3 (IGFBP-3) is a member of the insulin-like growth factor-binding protein family that binds IGF-I, blocking its mitogenic and antiapoptotic actions. In the absence of IGFBP-3, IGF-I binds and activates insulin-like growth factor-I receptor (IGFIR) and EGFR, commonly overexpressed in NSCLC, 5, 6 which signal through the PI3 kinase (PI3K)/Akt pathway, having a crucial role in cell growth, proliferation and survival. 7 In addition, genetic and epigenetic alterations account in multiple genes in the pathway. 8, 9 Furthermore, aberrant hypermethylation is a common epigenetic mechanism for the silencing of IGFBP-3 in several tumor types, including NSCLC. [10] [11] [12] The IGFBP-3/IGF-I/IGFIR axis exemplifies redundant routes to induce resistance to many drugs. 13 First, many proteins belonging to this pathway mediate chemotherapy resistance in NSCLC through the activation of Akt/mTOR (mammalian target of rapamycin) signaling. 14, 15 Second, a model of acquired resistance to EGFR tyrosine kinase inhibitors showed IGFBP-3 downregulated without changes in IGF-I and II levels, suggesting that EGFR tyrosine kinase inhibitor-resistant cells adopted IGFIR pathway in addition to EGFR/ErbB-3 to activate PI3K, 5 although possible mechanisms underlying IGFBP-3 downregulation and further IGFIR activation were not described. Third, we have reported that reduction of IGFBP-3 expression by promoter methylation is involved in CDDP resistance process in NSCLC; 16 probably as a result of a higher amount of IGF-I available to bind its canonical receptor. All these data suggest that an isolated alteration is not enough to induce resistance to cancer therapies.
In order to design a translational-based profile to predict resistance in NSCLC, more comprehensive information is necessary regarding the IGFBP-3/IGFI/IGFIR axis. To evaluate this hypothesis, we have used cellular models of CDDP-acquired resistance with different IGFBP-3 promoter-methylation status to study the alterations in the PI3K signaling pathway through EGFR and IGFIR. Then we have tested these data into a cohort of 25 NSCLC specimens with previously known in vitro CDDP sensitivity to calculate minimum requirements to predict resistance. Finally, we have computed likelyhood ratios and nomograms for clinical practice. In this regard, our results suggest that our approach that combines IGFBP-3 methylation status together with the AKT, IGFIR and EGFR activation enables the identification of CDDP responders and suggest future drugs combinations to optimize CDDPbased NSCLC therapy.
RESULTS

IGFBP-3 methylation induces the phosphorylation of AKT in CDDPresistant human cancer cell lines
To determine whether the resistance to CDDP mediated by IGFBP-3 promoter-methylation 16 correlates with the activation of the PI3K/AKT cellular pathway, we used the matched CDDP-sensitive/ resistant cell lines 41S/41R, H460S/H460R and H23S/H23R. 16 We first analyzed the IGFBP-3 expression that was dramatically decreased in the resistant cell line 41R, whereas no changes were observed in H460R cells, compared with their parental lines. Additionally, H23S cells (that harbors a semimethylated IGFBP-3 promoter 16 ) showed less IGFBP-3 expression than 41S and H460S cells, confirmed by the decreased ratio between IGFBP-3/GAPDH signals. The matched H23R cells harbor a more densely methylated promoter, 16 in line with the decrease observed in the gene expression (Figure 1a, left panel) . We then confirmed the presence of IGFBP-3 promoter hypermethylation in 41R and H23R cells by methylation-specific PCR, whereas it was unmethylated in H460R cells, (Figure 1a , right panel). Supporting our hypothesis Figure 1 . Association between IGFBP-3 promoter methylation status, gene expression levels and AKT activation. (a) Paired-matched cell lines 41S/R, H460S/R and H23S/R present different IGFBP-3 expression profile measured by RT-PCR (left panel) and also different gene methylation status (right panel). GAPDH mRNA was co-amplified as a loading control and the IGFBP-3 promoter methylation was analyzed using methylation-specific PCR (MSP). The presence of a PCR product in the methylated lane (M) indicates methylated alleles for IGFBP-3. Tumor cell lines H1299 and A549 were used as positive and negative controls (NC), respectively. (b) Schemas representing the different status of the IGFIR/PI3K/AKT pathway proposed for the CDDP-resistant or -sensitive cell lines, regarding the IGFBP-3 level. (c) Cells were seeded and 24 h later incubated in serum-depleted medium for 24 h, then treated with the indicated CDDP doses for 6 h. Total cell protein (20 mg) was subjected to WB and the membranes were hybridized with antibodies against p-AKT, AKT, PTEN and a-tubulin as a loading control. (Figure 1b) , there was a strong phosphorylation of AKT in all CDDP doses tested in the resistant cell line 41R (Figure 1c ) that was not due to increased AKT basal level, and cell line H23R presented a wider CDDP dose-response activation of AKT (2 mg/ml) in comparison with the H23S cells (1 mg/ml) (Figure 1c ). In addition, no changes in either p-AKT or AKT levels were visible in the cell line H460R, compared with the parental cells. The phosphatase and tensin homolog (PTEN) levels were not affected in 41S/R and H460S/R cells and were undetectable in H23S/R cells.
The response to CDDP is mediated by IGFBP-3 expression through the AKT function To confirm that IGFBP-3 expression was linked to CDDP sensitivity through AKT-phosphorylation, we chose 41R cells to again induce the IGFBP-3 expression through both gene overexpression and epigenetic reactivation.
IGFBP-3 was successfully reexpressed in 41R cells among different CDDP doses tested (0, 1, 2 and 3 mg/ml) (Figure 2a) , lowering the AKT phosphorylation to intermediate levels between 41R and 41S cells transfected with the empty vector (Figure 2b ). PTEN levels were not modified, as previously observed (Figure 1d ). We then examined whether the decrease in AKT activation induced changes in sensitivity to CDDP; IGFBP-3 was reexpressed in 41R cells 24 h after transfection, an effect remaining 72 h later, with 143% efficiency, compared with 41R cells transfected with the empty vector (Figure 2c ). IGFBP-3 overexpression induced an increase in CDDP sensitivity compared with the controltransfected cells, resulting in a decrease in the IC50 value in response to CDDP (1.15 mg/ml vs 1.91 mg/ml; Po0.001) (Figure 2d Next, to verify the role of AKT in the acquired resistance to CDDP, we first inhibited the AKT activation using LY294002, and then the AKT expression by small interfering RNA (siRNA), in the cell lines 41S/41R. As expected, 41S cells were not affected by LY294002 treatment, as this cell line lacks basal phosphorylation of AKT; however, in 41R cells treatment reduced the p-AKT levels (Figure 3a) , inducing a significant change in cell mortality at 1.5 and 2 mg/ml of CDDP (Po0.05 and Po0.001, Figure 3b ). In addition, AKT expression was inhibited in 41R cells 24 h after siRNA transfection, an effect remained after 48 h, compared with cells transfected with control-RNA interference (RNAi) (NC) (Figure 3c ). AKT silencing in resistant cells (41R RNAi AKT) induced an increase in CDDP sensitivity, compared with cells transfected with NC (41R RNAi NC) (Figure 3d ), resulting in a significant decrease in the IC50 value in response to CDDP (1.20 mg/ml vs 2.10 mg/ml, Po0.001). Regarding CDDP sensitivity, these cells showed no significant differences from the 41S cells transfected with NC (41S RNAi NC) (P ¼ 0.07) (Figure 3e ).
IGFBP-3 expression regulates the IGFIR/AKT pathway inducing cell sensitivity to CDDP To assess which receptor is involved in the observed AKT phosphorylation, we measured p-EGFR, EGFR, p-IGFIR and IGFIR protein levels in response to the increasing doses of CDDP in our panel of three matched sensitive/resistant cell lines, together with EGF or IGFI treatment as positive controls.
EGF stimuli induced the activation of EGFR only in 41S cells. In addition, in 41R cells we found lower levels of EGF receptor in all CDDP doses tested ( Figure 4a ). The IGFI stimuli induced the activation of the IGFIR only in the resistant cell line 41R. Furthermore, IGFIR was active at basal conditions in 41R cells (0 mg/ml CDDP), activation maintained at all CDDP doses tested, whereas it was activated in 41S only at high doses (2-3 mg/ml) ( Figure 4a ). Activation of the IGFIR observed in 41R cells shrinks when IGFBP-3 is overexpressed ( Figure 4b) ; effect, observed in all CDDP doses tested. Additionally, no changes were observed in either the EGFR levels or in its activation when IGFBP-3 is overexpressed ( Figure 4b ). As expected, no changes in EGFR or IGFIR activation were observed in H460 and H23 cells, as no noticeable changes in IGFBP-3 expression or in AKT activation were initially found when cells developed an acquired resistance to CDDP (Supplementary Figure 2) . 
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Using immunofluorescence we also found that serum-starved 41S cells showed prominent membrane IGFIR and partial receptor internalization after IGFI stimuli. However, its distribution was affected in 41R cells, in which we detected mainly the intracellular IGFIR that strongly increased with IGFI treatment (Figure 4c ). IGFI also induced IGFIR nuclear translocation in 41R cells, according to previous data. 17 We next confirmed some basal EGFR membrane presence only in 41S cells that translocate into the cytoplasm when EGF was added (Figure 4d ). In addition, we did not find any changes in the EGFR mRNA levels between 41S and 41R cells (data not shown).
To determine that these results were not specific for the cell lines 41S/41R, we used the cell lines PANC-1, H1299, H727 and HT29 that harbor a methylated promoter for the IGFBP-3 gene and different IC50 to CDDP. 16 We first confirmed that all cell lines lacked or expressed IGFBP-3 at a low level (Ø) (Supplementary  Figure 3a) ; next, the IGFBP-3 reexpression induced a severe decrease in cell survival compared with cell lines transfected with the empty vector (Supplementary Figure 3b) .
We also found that IGFBP-3 overexpression in H1299 lung cancer cells (Figure 5a ) was concomitant with a decrease in the IGFIR and AKT phosphorylation levels after CDDP treatment (Figures 5b and c) . The same pattern was found in the cell line PANC1 for pIGFIR and pAKT levels at 2 and 3 mg/ml CDDP. At the same CDDP doses, pAKT levels in H727 cells also decreased after IGFBP-3 overexpression; however, IGFIR levels were almost undetectable, preventing the confirmation of any correlation. No changes in the activation of AKT and IGFIR were observed in HT29. In addition, the activation of EGFR was not modified in every cell line (Figures 5b and c) .
Combination of IGFBP-3 promoter methylation with IGFIR, EGFR and AKT activation status predicts resistance or sensitivity to CDDP in NSCLC samples As a translational approach, we further analyzed the correlation between IGFBP-3 methylation and the phosphorylation of IGFIR, EGFR and AKT in NSCLC primary tumors. In a previous study, we exposed 36 NSCLC fresh tumors to different CDDP concentrations and analyzed their IGFBP-3-methylation status, comparing the results with the clinical history. 16 According to Receiver operating characteristic (ROC) methodology, the IC50 index divided patients into two groups, regarding sensitivity or resistance to CDDP. From that cohort of NSCLC patients, we have assessed EGFR, IGFIR and AKT protein activation by immunohistochemical analysis in 25 surgical specimens (Supplementary Table 1 and Figure 6a ). First, we found a predominant activation of IGFIR, but not EGFR, in NSCLC patients (32 vs 16%). In addition, 75% of patients with phosphorylated IGFIR, showed concomitant activation of AKT (Supplementary Table 1) , and 87.5% of NSCLC patients with IGFI receptor activation (seven out of eight patients) were resistant to CDDP. Furthermore, the combination of IGFBP-3 methylation together with IGFIR and/or AKT phosphorylation only concurred in NSCLC patients resistant to CDDP, whereas no concomitant results from these parameters were found in CDDP-sensitive NSCLC patients.
With all these data we have developed a predictive panel, which considers that a sample needs at least two modifications to get a true phenotypic change in terms of CDDP response. Our predictive test found 15 patients with an apparent response to CDDP (S) as their harbored one or less events in our predictive panel. In all, 12 of them were truly sensitive to CDDP when confronted to IC 50 data. On the opposite, 10 patients should have been resistant to CDDP accordingly to our test (R) and in fact only one failed this prediction (Supplementary Table 1 ). When all data were computed in a 2 Â 2 contingency table, the accuracy and precision of this test was 0.84 and 0.9, respectively (P ¼ 0.0062). When we consider that a sample needs at least two modifications to get a true phenotypic change in terms of CDDP response (twosided P ¼ 0.0025) with a positive post-test probability of 90% (positive likelihood ratio 9.75) and a negative post-test probability of 20% (Figure 6b ).
DISCUSSION
The literature provides evidence that there is an increase of DNA hypermethylation after CDDP exposure in vivo and in vitro; 2, 3, 16, [18] [19] [20] however, the molecular mechanisms still remain unclear. Even though it was thought that CDDP could not have epigenetic effects because it is a DNA crosslinking agent; however, significant evidence is emerging that links the loss of gene expression in NSCLC by DNA CpG methylation with CDDP resistance. In fact, pulsed exposure to CDDP has been shown to result in drug-induced DNA hypermethylation in lung adenocarcinoma (HTB-54), rhabdomyosarcoma (CCl-136) and ovarian human cancer cells (A2780), [18] [19] [20] an event that has also been reported in vivo. 2, 3 It is well known that the metal toxicity induced by CDDP is because of reactive oxygen species production and the subsequent induction of oxidative stress. [21] [22] [23] Oxidative stress induces a complex cellular response, in which genetic and epigenetic alterations are involved. As an example, local generation of NO and superoxide anion O 2 À may activate RAS, which ultimately may induce the expression of DNA methyltransferases 1 and DNA methyltransferases 3B, and consequently the increase of DNA methylation. 24 This DNA methylation may affect the expression of specific genes directly or as a result of microRNA silencing, in which mRNA targets are epigenetic regulators. This occurs with the miR29 family, which has been shown to be methylated in lung cancer and to directly target DNMT3A and 3B and indirectly DNA methyltransferases 1 expression. 25 In fact, the DNMTs family has been reported to be upregulated in CDDP-resistant clones established from the human cervix cancer cell line ME180. 26 This increase in expression seems to mediate the resistance to CDDP in mouse neuroblastoma, indicating that DNA methylation has a role in the occurrence of that resistance. 27 In our case, loss of IGFBP-3 expression, through promoter hypermethylation, results in a reduction in tumor cell sensitivity to CDDP in NSCLC. 16 We cannot also discard possible aberrant expression of epigenetic regulators as histone demethylases or deacetilases. Histone deacetylases (HDACs) are important regulators of many oxidative stress pathways including those involved with both sensing and coordinating the cellular response to oxidative stress. In particular, aberrant regulation of these pathways by HDACs may have a critical role in cancer progression. 28 The HDAC4 and HDAC6 proteins are associated with specific regions of the IGFBP-3 gene, which coincides with histone H4 deacetylation on these regions that can ultimately silence gene expression. 29 In fact, we have shown that the use of histone deacetylation inhibitors in combination with demethylating agents restored IGFBP-3 expression. 16 This aberrant HDAC activity may be caused by the overexpression of metastasis-associated protein 1 and 2, which have been reported in NSCLC and have been shown to functionally associate with HDACs. 30 The hypoxic stress also induces an increase in diMe-histone H3 lysine 9 (H3K9), which is a critical epigenetic marker for gene repression and silencing and has an essential role in carcinogenesis. This increase may be mediated first by the inhibition of H3K9 demethylation processes, 31 probably secondary to the increase in the enzyme JMJD1B that demethylates trimethylated H3K9 to dimethylated H3K9. This process has been observed in renal cancer cells under hypoxic conditions. 32 Alternatively, the increase may be secondary to increased levels of DNA methyltransferases 1 after CDDP treatment, as it has been reported that dual DNA methyltransferases 1/3b knockout reduced the level of diMe-H3K9. 33 However, for the majority of those aberrant epigenetics events, it is not particularly clear whether they are associated with responses to chemotherapy or they are occurring by chance owing to a methylator phenotype, or simply as random methylation events during platinum selection or DNA damage induction. 34 In an analogy to the concept of driver and passenger, methylation changes occurring during carcinogenesis could either represent drivers of chemoresistance based on their potential to provide the cell with a selective advantage, or passenger events, with no substantial impact on chemosensitivity. 35 Therefore, it is important to characterize each methylation event identified as a result of CDDP exposure, as many of them could not be related with chemotherapy resistance.
In the current study, we have used three paired sensitive/ resistant cell lines that present a different IGFBP-3 gene expression and promoter methylation profile to determine whether this resistance to CDDP is mediated by the activation of the PI3K/AKT cellular pathway. In fact, the resistance to CDDP in 41R and H23R cells was concomitant with the presence of IGFBP-3 hypermethylation and the decrease in IGFBP-3 expression. However, H460R cells harbored an unmethylated IGFBP-3 promoter, indicating that resistance to CDDP in these cells is independent of an IGFBP-3 epigenetic regulation, making them a perfect negative control for this study. Supporting our hypothesis, IGFBP-3 hypermethylation correlated with a strong phosphorylation of AKT in 41R cells. Interestingly, H23S that harbors a semimethylated promoter showed basal AKT phosphorylation, that resulted in a wider CDDP dose-response activation of the protein when the cell line acquires a more densely hypermethylated promoter 16 as a result of resistance establishment (H23R). As expected, no changes were visible in the cell line H460R. We discarded a role for PTEN mediating resistance to CDDP in our models, as we did not find any alterations in its levels in H460S/R and 41S/R cells; and in the cell line H23, that harbors a nonsense mutation (PTEN_R233*), 36 PTEN levels were undetectable. In fact, although PTEN can be altered by methylation, mutation and homozygous deletion in human tumors, in NSCLC those alterations occur at low frequency. 36, 37 These results indicate that IGFBP-3 methylation induces the phosphorylation of AKT in CDDP-resistant human cancer cell lines. In fact, AKT is responsible in part, of the resistance to the agent in these cells, as IGFBP-3 overexpression, lowered the AKT phosphorylation levels inducing an increase in sensitivity to CDDP in 41R cells, reaching an intermediate resistant index between 41S and 41R cells. Similarly, the epigenetic reactivation of IGFBP-3 expression also increased the sensitivity to CDDP in these cells. We also provide further evidence about the direct role of AKT in the acquired resistance to CDDP, as both the inhibition of AKT phosphorylation and the AKT silencing induced an increase in cell mortality and in cell sensitivity to CDDP, resulting in a significant decrease in the IC50 value in response to CDDP in 41R cells.
Those results indicate that AKT phosphorylation has a role in the survival process to CDDP in 41R cells, supporting previous data Identification for NSCLC CDDP-responder patients M Corté s-Sempere et al that report an activation of the AKT pathway in the resistance to CDDP in lung cancer cells. 38, 39 Therefore, these global results provide evidence confirming IGFBP-3 promoter hypermethylation as an event that mediates the response to CDDP through the activation of AKT.
Then, we assess through which receptor is AKT activated in the acquired resistance to CDDP. Interestingly, we found lower levels of EGF receptor in 41R cells; this effect of CDDP inducing a decrease in EGFR protein expression has been previously reported in MDA-MB-468 cells. 40 Conversely, the IGFIR was activated only in 41R cells, probably because IGFBP-3 is expressed normally in 41S cells, and could be sequestering IGF-I blocking the receptor activation. In fact, IGFI mediates the sustained phosphorylation of AKT, which is essential for a long-term survival in the protection from toxic agents in glial cells. 41 In addition, the IGFIR activation in 41R cells shrank when IGFBP-3 was overexpressed, confirming the role of IGFBP-3 in the AKT activation through IGFIR phosphorylation. We next confirmed the presence of membrane IGFIR and partial receptor internalization after IGFI stimuli in 41S cells, whereas in 41R cells we detected mainly the intracellular IGFIR that strongly increased with IGFI treatment, consistent with receptor internalization. 42 The chronic receptor activation in 41R cells could be mediated by the downregulation of IGFBP-3 expression that causes continuous IGFI cell exposure. This growth factor stimulus could ultimately sustain the Akt phosphorylation observed in these cells through the described IGFIR internalization and recycling process. 41 Although we did not find any changes in the EGFR mRNA levels between 41S and 41R cells, there was a very low EGFR signaling in 41R cells compared with the parental sensitivity, indicating that alterations may be at posttranscriptional level, confirming our data obtained by western blot (WB). These results could explain why several phase III randomized trials combining standard chemotherapeutics with gefitinib, an inhibitor of EGFR tyrosine kinase domain, have failed to show benefits in advanced NSCLC patients. 43, 44 Those results were not specific for the cell lines 41S/41R, as IGFBP-3 overexpression in the lung and pancreatic cancer cell lines H1299 and PANC-1, induced a notable decrease in the IGFIR phosphorylation after CDDP treatment, concomitant with a decrease in pAKT levels; same pattern regarding AKT phosphorylation was also found in the H727 lung cancer cell line. Those results indicate that IGFBP-3 expression regulating the IGFIR/AKT pathway is probably a common mechanism of cell sensitivity to CDDP in different tumor types. In addition, the IGFBP-3 overexpression also induced a severe decrease in cell survival in the four human cancer cell lines tested, which harbor a methylated IGFBP-3 promoter; moreover, there was a correlation between the IC50 to CDDP and the mortality rate in those cells overexpressing IGFBP-3. This result confirms a strong correlation between IGFBP-3 expression and cell mortality regarding sensitivity to CDDP. Explained in terms of translational application, those tumors lacking IGFBP-3 expression could be suitable for targeted therapy with demethylating agents, as there is a connection between their CDDP resistance and the cell mortality expected after IGFBP-3 reexpression.
We ultimate this study translating to the clinic our laboratory results, in order to gain insight into the cellular pathways involved in the CDDP-acquired resistance process in NSCLC primary tumors. We found predominant activation of IGFIR, but not EGFR in NSCLC patients, being the pEGFR percentage similar to previously reported data. 45 In addition, the activation of IGF-I receptor was a frequent event in NSCLC primary tumors that were resistant to CDDP, and those patients with phosphorylated IGFIR showed concomitant activation of AKT. Those results could explain previous data showing a constitutive AKT phosphorylation through the activation of IGFIR in cells resistant to EGFR inhibition. 46 Furthermore, both IGFBP-3 promoter methylation and IGFIR/AKT phosphorylation concurs only in CDDP-resistant NSCLC patients, indicating that IGFBP-3 methylation-derived deficiency could mediate the resistance to CDDP in NSCLC patients though the activation of the IGFIR/AKT pathway. In addition, combination of IGFBP-3 promoter methylation with IGFIR, and/or AKT, and/or EGFR activation status could be used to predict resistance or sensitivity to CDDP in NSCLC samples. In fact, in this manuscript we present a predictive test that considers that a NSCLC sample needs at least two modifications out of these four: IGFBP3 methylation, IGFIR phosphorylation, EGFR phosphorylation and AKT phosphorylation, to get a true phenotypic change in terms of CDDP response, with an accuracy and precision of 0.84 and 0.9, respectively, and with a positive likelihood ratio 9.75. Obviously, it is necessary to evaluate this test with additional populations to prove its clinical utility of selecting patients with a high probability to respond to CDDP alone or with a combined therapy based on IGFIR, EGFR and/or AKT inhibitors.
MATERIALS AND METHODS
Cell lines, drugs and treatments H-460 and H-23 human NSCLC cell lines were purchased from the ATCC (American Type Culture Collection; Manassas, VA, USA), their CDDPresistant variants H23R and H460R were established previously in our laboratory 16 and cultured as recommended. The CDDP-sensitive andresistant ovarian cancer cell lines 41M and 41MR, hereafter called 41S and 41R, respectively, were provided by Dr L Kelland and maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. Additional four human cancer cell lines (H1299, H727, HT-29 and PANC1) were purchased from the ATCC or the ECACC (European Collection of Cell Cultures; Sigma-Aldrich, Madrid, Spain) and cultured as recommended. 5-aza-2 0 -deoxycytidine and Trichostatin A; Sigma-Aldrich) were used following methodology previously described. 11 CDDP was obtained from Farma-Ferrer (Barcelona, Spain) and the specific PI3K inhibitor LY-294002 was obtained from Calbiochem (Darmstadt, Germany).
For reexpression studies, 41R cells were split to low density and exposed to 5-aza-2 0 -deoxycytidine (5 mM) and Trichostatin A (300 nM) or to phosphatebuffered saline and ethanol (mock cells) at different CDDP doses, followed by the cell viability analysis to CDDP comparing sensitive vs resistant cell lines before and after the epigenetic treatment, as previously described. 38 Simultaneously, same experimental groups were seeded at 700 000 cells per p60 plate and treated as described above, in order to test the IGFBP-3 levels by quantitative reverse transcriptase PCR (RT-PCR).
For the PI3K pathway inhibition assay, the 41S and 41R cells were treated 24 h after being seeded, either with the LY-294002 inhibitor or with dimethyl sulfoxide as NC for 1.5 h; then CDDP was added and cell viability measured. Simultaneously, same experimental groups were treated with dimethyl sulfoxide or LY-294002 as described above, in order to test by WB the inhibition of AKT phosphorylation as internal control.
NSCLC clinical samples and data collection
Formalin-fixed paraffin-embedded surgical specimens were obtained from 25 patients who had undergone a complete resection (R0) for a histologically confirmed, early NSCLC. All patients had both a perioperative positron emission tomography-computed tomography scan showing localized disease and a pathological confirmation of stage I or II. In addition, an age of X18 years, intraoperative mediastinal node dissection for reliable mediastinal staging or biopsy of nodes at Node 3, without any evidence of disease were the inclusion criteria. Stage III, any involvement of tracheobronchial angle nodes (station 10), mixed histological features and previous diagnosis of cancer within the last 5 years were the exclusion criteria. Histological slides obtained from each block were reviewed by two expert pathologists to confirm diagnosis and to guarantee at least 90% tumoral content. Follow-up was performed according to the criteria used in the Medical Oncology Division from the H La Paz, including clinical assessments and thorax computer tomography (CT) every 3 months for 2 years and every 6 months thereafter. Clinical, pathological and radiological data were recorded by an independent observer at the H La Paz and blinded for statistical analysis.
DNA and RNA extraction, bisulfite modification, methylationspecific PCR and quantitative RT-PCR DNA from human cancer cell lines was isolated and bisulfite modified as described, 11 and used to analyze IGFBP-3 methylation status. MethylationIdentification for NSCLC CDDP-responder patients M Corté s-Sempere et al specific PCR amplification was performed with specific primers to detect methylated or unmethylated modified DNA according to previous data. 16 Total RNA from human cancer cell lines was isolated as previously described. 11 Reverse transcription and quantitative RT-PCR analysis were performed as described. 16 Samples were analyzed in triplicate using the StepOnePlus Real-Time PCR system (Applied Biosystems, Carlsbad, CA, USA). Primers and probe for IGFBP-3 expression analysis were purchased from Applied Biosystems (Hs00181211_m1).
Semiquantitative PCR reactions for IGFBP-3 were performed as described. 16 Plasmids and siRNA transfections For IGFBP-3 overexpression, cell lines were transfected (Lipofectamine 2000, Invitrogen, Barcelona Spain) with either pCMV5 expression vector containing human IGFBP-3 complimentary DNA (cDNA; Origene, Rockville, MD, USA) or the empty vector (pCMV5) as recommended. Twenty-four hours later, cells were seeded in 24-well dishes for cell viability assays or for cell mortality rate estimation. Simultaneously, same experimental groups were either harvested at same incubation periods to test by RT-PCR IGFBP-3 overexpression or followed a CDDP treatment at different doses for protein levels estimation by WB.
For AKT siRNA assays, 41S and 41R cells (700 000 cells per plate) were transfected with 100 nM AKT-siRNA or NC-siRNA (HSS105266, Select-RNAi and 2935-200, RNAi-Negative Control, Invitrogen), according to the manufacturer's directions. For the viability assay, cells were seeded in 24-well dishes at 80 000 cells per well 24 h after transfection with AKTsiRNA or siRNA-control, 12 h later cells were treated with CDDP and cell viability was quantified. In parallel, same experimental groups were harvested at 24 and 72 h after siRNA transfection, as a time course to test by WB the preservation of siRNA effects on AKT protein levels.
WB, immunofluorescence and immunohistochemical analysis
Cell lines were cultured at a density of 10 6 cells by 60-mm plate, shifted into medium containing 0.5% fetal bovine serum during 24 h, then stimulated with CDDP with different doses. Whole-cell extracts and WB were performed as described. 47 For fluorescence microscopy, cells were grown onto coverslips, and 48 h later were treated with EGF at 20 ng/ml (Sigma-Aldrich) or IGF-I at 100 ng/ ml (Peprotech, London, UK) for 30 min as stimuli controls, then fixed with paraformaldehyde, permeabilized with Triton X-100 and incubated with secondary antibodies coupled to the fluorescent dye alexa-fluor 488 (Molecular Probes, Barcelona, Spain). Images were acquired on a Confocal Espectral Leica TCS SP5 microscope (Leica, Wetzlar, Germany).
Twenty-five formalin-fixed paraffin-embedded, NSCLC surgical specimens were used for immunohistochemistry analysis. Antigens were retrieved with the Dako buffer citrate pH 9 in a DAKO PT Link for 20-40 min (Dako, Glostrup, Germany). Sections were stained using an automated system DAKO Austostainer. Immunohistochemistry was performed using the Dako Envision Flex kit. Immune reactions were developed with diaminobenzidine and sections were counterstained with Harris' hematoxylin. As NCs, adjacent sections were subjected to same procedure with the antibodies incubated with the appropriate blocking peptide when possible or omitting the primary antibody when peptide was not available. Sections of human breast cancer tissue were used as positive controls.
Antibodies used were anti-AKT (BD Biosciences, San Jose, CA, USA), pAKT-Ser473, PTEN, EGFR, pEGFR-Tyr1068 (1H12, WB), pEGFR-Tyr1068 (D7A5, IHC; Cell Signaling, Danvers, MA, USA), anti-IGFIR, anti-pIGFIRTyr1161 (Santa Cruz Biotechnology, Heidelberg, Germany), anti-phospho AKT-pS473 (Dakopatts, Glostrup, Denmark) and anti-a-tubulin (SigmaAldrich).
Statistical analysis
We have evaluated our data in terms of accuracy and precision in a binary classification in order to identify or exclude a potential response to CDDP. In this regard, response to CDDP measured by in vitro IC 50 was considered the gold standard (resistant or sensitive). Predicted test value for a tissue sample was considered resistant to CDDP if it had two or more positive results when pAkt or pIGFIR, or pEGFR or IGFBP-3-methylation was evaluated. Otherwise, the sample was considered as sensitive. Then we confronted the predicted value to the true condition determined by CDDP IC 50 to calculate accuracy and precision, likelihood ratios, sensitivity and specificity. Additionally, we used the Fisher's exact test within a 2 Â 2 contingence table to calculate the association between our diagnostic test and the true outcome of analyzed samples in terms of CDDP IC 50 . ABBREVIATIONS ATCC, American Type Culture Collection; BS, bisulfite sequencing; CDDP, cisplatin; DFS, disease-free survival; ECACC, European Collection of Cell Cultures; EGFR, epidermal growth factor receptor; IGFBP-3, insulin-like growth factor-binding protein-3; IGFIR, insulin-like growth factor-I receptor; MSP, methylationspecific PCR; NSCLC, non-small cell lung cancer.
